Tissue biomarkers of early vascular aging

Background: The ongoing demographical shift is leading to an unprecedented aging of the population. As a consequence, the prevalence of age-related diseases, such as atherosclerosis and its thrombotic complications is set to increase in the near future. Endothelial dysfunction and vascular stiffening characterize arterial aging and set the stage for the development of cardiovascular diseases. Atherosclerotic plaques evolve over time, the extent to which these changes might affect their stability and predispose to sudden complications remains to be determined. Recent advances in imaging technology will allow for longitudinal prospective studies following the progression of plaque burden aimed at better characterizing changes over time associated with plaque stability or rupture. Oxidative stress and inflammation, firmly established driving forces of age-related CV dysfunction, also play an important role in atherosclerotic plaque destabilization and rupture. Several genes involved in lifespan determination are known regulator of redox cellular balance and pre-clinical evidence underlines their pathophysiological roles in age-related cardiovascular dysfunction and atherosclerosis. Objective: The aim of this narrative review is to examine the impact of aging on arterial function and atherosclerotic plaque development. Furthermore, we report how molecular mechanisms of vascular aging might regulate age-related plaque modifications and how this may help to identify novel therapeutic targets to attenuate the increased risk of CV disease in elderly people.

SIRT1 as a Novel Potential Treatment Target for Vascular Aging and Age-Related Vascular Diseases

Current Molecular Medicine ◽

10.2174/1566524011307010155 ◽

2012 ◽

Vol 13 (1) ◽

pp. 155-164 ◽

Cited By ~ 2

Author(s):

F. Wang ◽

H.-Z. Chen ◽

X. Lv ◽

D.-P. Liu

Keyword(s):

Vascular Diseases ◽

Potential Treatment ◽

Vascular Aging ◽

Treatment Target ◽

Age Related

ME 04-3 EPIDEMIOLOGY AND CONSEQUENCES OF EARLY VASCULAR AGING

Journal of Hypertension ◽

10.1097/01.hjh.0000501486.01861.11 ◽

2016 ◽

Vol 34 (Supplement 1) ◽

pp. e541

Author(s):

Junichiro Hashimoto

Keyword(s):

Vascular Aging

Effect of parathyroidectomy on bone tissue biomarkers and body composition in patients with chronic kidney disease and secondary hyperparathyroidism

European Journal of Clinical Nutrition ◽

10.1038/s41430-020-00829-7 ◽

2021 ◽

Author(s):

Flavia Ramos de Siqueira ◽

Karin Carneiro de Oliveira ◽

Wagner Vasques Dominguez ◽

César Augusto Madid Truyts ◽

Rosa Maria Affonso Moysés ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Body Composition ◽

Kidney Disease ◽

Secondary Hyperparathyroidism ◽

Bone Tissue ◽

Tissue Biomarkers

Early vascular aging risk assessment in patients with metabolic syndrome

European Heart Journal ◽

10.1093/ehjci/ehaa946.2919 ◽

2020 ◽

Vol 41 (Supplement_2) ◽

Author(s):

A Salasyuk ◽

S Nedogoda ◽

I Barykina ◽

V Lutova ◽

E Popova

Keyword(s):

Risk Factors ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Risk Assessment ◽

Metabolic Syndrome ◽

Vascular Aging ◽

Clinical Markers ◽

Cvd Risk ◽

Vascular Age

Abstract Background Metabolic syndrome (MetS) and abdominal obesity are one of the most common CVD risk factors among young and mature patients. However, the currently used CVD risk assessment scales may underestimate the CV risk in people with obesity and MS. Early vascular aging rather than chronological aging can conceptually offer better risk prediction. MetS, as accumulation of classical risk factors, leads to acceleration of early vascular aging. Since an important feature of MetS is its reversibility, an adequate risk assessment and early start of therapy is important in relation to the possibilities of preventing related complications. Purpose To derive a new score for calculation vascular age and predicting EVA in patients with MetS. Methods Prospective open cohort study using routinely collected data from general practice. The derivation cohort consisted of 1000 patients, aged 35–80 years with MetS (IDF,2005 criteria). The validation cohort consisted of 484 patients with MetS and carotid-femoral pulse wave velocity (cfPWV) values exceeding expected for average age values by 2 or more SD (EVA syndrome). Results In univariate analysis, EVA was significantly correlated with the presence of type 2 diabetes and clinical markers of insulin resistance (IR), body mass index (BMI), metabolic syndrome severity score (MetS z-score), uric acid (UA) level, hsCRP, HOMA-IR, total cholesterol (TC), triglycerides (TG), heart rate (HR), central aortic blood pressure (CBP), diastolic blood pressure (DBP). Multiple logistic regression shown, that presence of type 2 diabetes and IR were associated with greater risk of EVA; the odds ratios were 2.75 (95% CI: 2.34, 3.35) and 1.57 (95% CI: 1.16, 2.00), respectively. In addition, the risk of having EVA increased by 76% with an increase in HOMA-IR by 1 unit, by 17% with an increase in hsCRP by 1 mg/l, by 4% with an increase in DBP by 1 mm Hg, and by 1% with each 1 μmol / L increase in the level of UA. The area under the curve for predicting EVA in patients with MetS was 0,949 (95% CI 0,936 to 0,963), 0,630 (95% CI 0,589 to 0,671), 0,697 (95% CI 0,659 to 0,736) and 0,686 (95% CI 0,647 to 0,726), for vascular age, calculated from cfPWV, SCORE scale, QRISK-3 scale and Framingham scale, respectively. Diabetes mellitus and clinical markers of IR (yes/no), HOMA-IR and UA level were used to develop a new VAmets score for EVA prediction providing a total accuracy of 0.830 (95% CI 0,799 to 0,860). Conclusion cfPWV at present the most widely studied index of arterial stiffness, fulfills most of the stringent criteria for a clinically useful biomarker of EVA in patients with MetS. Although, parallel efforts for effective integration simple clinical score into clinical practice have been offered. Our score (VAmets) may accurately identify patients with MetS and EVA on the basis of widely available clinical variables and classic cardiovascular risk factors can prioritize using of vascular age in routine care. ROC-curves for predicting EVA in MetS Funding Acknowledgement Type of funding source: None

Identifying potential metabolic tissue biomarkers for papillary thyroid cancer in different iodine nutrient regions

Endocrine ◽

10.1007/s12020-021-02773-3 ◽

2021 ◽

Author(s):

Qihao Sun ◽

Hongjian Zhao ◽

Zhiyong Liu ◽

Fengqian Wang ◽

Qian He ◽

...

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Cancer ◽

Papillary Thyroid ◽

Tissue Biomarkers

Alterations of long non-coding RNA and mRNA profiles associated with extracellular matrix homeostasis and vascular aging in rats

Bioengineered ◽

10.1080/21655979.2021.1889129 ◽

2021 ◽

Vol 12 (1) ◽

pp. 832-843

Author(s):

Qianqin Li ◽

Zezhou Xiao ◽

Yongsheng Wang ◽

Ximao Liu ◽

Hao Liu ◽

...

Keyword(s):

Extracellular Matrix ◽

Vascular Aging ◽

Non Coding Rna ◽

Long Non Coding Rna